Enterprise Value
195.1M
Cash
165.4M
Avg Qtr Burn
-7.456M
Short % of Float
9.21%
Insider Ownership
40.39%
Institutional Own.
58.06%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 2b Data readout | |
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Postpartum depression, Bipolar depression | Phase 2a Data readout | |
GH002 (IV mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 1 Data readout | |
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 1 Initiation |